Clinical Trial Update: Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating aspirin as an anti-inflammatory treatment in Fontan patients was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Single-ventricle Physiology

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: University of Michigan | Conditions: Fontan Procedure | Phase 4 | Status: TERMINATED | Results posted: 2018-05-18